Background for AI/ML Adoption

Recent AI and machine learning (ML) have seen rapid advances in data processing capabilities and predictive accuracy. Pharmaceutical companies are applying them during the development of combination products. Combination products integrate drugs and medical devices, and their design, testing, and regulatory pathways are complex, making traditional approaches time- and cost-intensive. AI/ML is gaining attention as a tool to reduce this complexity and improve efficiency.

Use Cases of AI in the Development Process

AI predicts chemical structures and biological activity during the candidate selection stage, and supports patient cohort selection and dose optimization during clinical design. For example, machine-learning models can quickly identify high-probability combinations from large experimental datasets. These technologies shorten development cycles and lower the risk of failure.

Impact on Regulatory and Quality Management

Combination products face stringent regulatory review, but AI-driven simulations can forecast safety and efficacy data in advance, strengthening submission dossiers. Moreover, AI enables real-time quality monitoring in manufacturing, automating regulatory compliance. This accelerates approval timelines and lowers market entry barriers.

Significance for the Market and Patients

When AI speeds up combination product development, drug-device combination therapies reach patients more quickly. This is especially promising for rare diseases and personalized medicine, offering innovative solutions. Consequently, the growth engine of the pharma-biotech sector is expected to expand.